Raad Z Gharaibeh
Associate Professor, Director, UF Health Cancer Center Microbiome Genomics
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
The intestinal microbiota has been shown to influence host-derived microRNAs (miRNAs), small regulatory RNAs involved in host-pathogen interactions. However, the specific role of individual bacterial species in modulating host extracellular vesicles (EV)-derived miRNA profiles remains unclear. We compared stool miRNA profiles from three groups: (i) Germ-free (GF) mice, (ii) mice colonized with a consortium of 13 bacteria (C13), and (iii) mice colonized with C13 and Campylobacter jejuni 81–176 (C13 + C. jejuni ). miRNA profiling revealed unique differential expression of 8 miRNAs in C13 vs GF, 38 in C13 + C. jejuni vs C13, and 159 in C13 + C. jejuni vs GF ( P adj < 0.05), indicating a substantial shift in host miRNA landscape following C. jejuni exposure. Notably, C13 + C. jejuni mice showed increased expression of miRNAs predicted to target bacterial virulence genes, suggesting a potential host response mechanism aimed at regulating microbial activity. Integration with spatial transcriptomics of the mouse colon revealed that specific EV-derived miRNAs, including mmu-miR-155-5p, mmu-miR-122-5p, mmu-miR-21a-5p, mmu-let-7i-5p, and mmu-miR-142a-3p target epithelial genes involved in immune regulation, inflammation, and barrier function. C. jejuni exposure selectively enriched these host miRNAs, suggesting a mechanism by which EVs modulate epithelial transcriptional responses and potentially influence microbial gene expression. In conclusion, C. jejuni infection modified host EV-derived miRNA expression profile that may have a potential to bind to the bacterial gene targets. IMPORTANCE Host-derived microRNAs (miRNAs) are known to regulate bacterial gene expression and maintain gut homeostasis. However, how these miRNAs survive harsh gut conditions to remain functional is not fully understood. This study tested whether extracellular vesicles (EV) carry microRNAs in the gut and whether infection with the enteric pathogen Campylobacter jejuni alters the microRNA profile packaged in these vesicles. We utilized fecal samples from mice, either maintained germ-free (absence of microbiota) or, C13 (defined 13 bacterial consortium), and C13 + C. jejuni to analyze the EV-derived miRNA pattern across the groups. Our results revealed distinct sets of miRNAs in each group and suggested possible interactions between these miRNAs and gene transcripts from both the host and bacteria. These findings provide new insights into how C. jejuni infection may change communication between the host and its microbiome, potentially affecting gut health and disease.
Year:
2026
The intestinal microbiota influences host susceptibility to Campylobacter jejuni ( C. jejuni ) infection. However, the interaction between specific intestinal bacteria and the C. jejuni- mediated host response is unclear. We established a defined consortium of bacteria to delineate C. jejuni -induced host responses. Three groups of germ-free (GF) Il10 -/- mice were used in this study: 1) mice colonized with a defined consortium of 13 bacterial isolates (C13) representing the four most prominent phyla in the mouse gut. 2) C13 plus C. jejuni 81-176 and 3) GF alone. The C13 + C. jejuni group induced significant intestinal inflammation and inflammatory mRNA gene expression compared to mice colonized with C13. 16S rRNA gene sequencing revealed an increased relative abundance of Escherichia and Paraclostridium in C13 + C. jejuni . Fluorescence in situ hybridization (FISH) and RNAscope integrated with spatial transcriptomics provided a high-resolution map of infection-induced gene expression, revealing localized immune responses and epithelial remodeling in defined colonic regions. Region-specific analysis further demonstrated that tissue-associated C. jejuni differentially modulates host gene expression compared to tissue-associated Enterobacteriaceae . Collectively, these findings demonstrate the potential of defined microbial consortia and spatially resolved transcriptomics to dissect the complex interplay between host, microbiota, and pathogens during enteric infection.
Year:
2025
Background Inflammatory bowel diseases (IBDs) are characterised by dysbiosis and a leaky gut. The NADPH oxidase dual oxidase 2 (DUOX2) is upregulated in patients with IBD, yet its role in driving the disease remains unclear. Objective We interrogated the functional consequences of epithelial DUOX2 activity for the host and microbiome. Design DUOX2 function was studied in mice with epithelial-specific DUOX2 overactivation (vTLR4), inactivation (vTLR4 DUOXA IEC-KO) and wild-type controls. We assessed the effect of dysbiosis on DUOX2 signalling and intestinal permeability (FITC-dextran, serum zonulin, bacterial translocation) with germ-free (GF) mice engrafted with IBD or healthy microbiota. RNA sequencing of colonic mucosa and microbiota and faecal metabolomics were used to characterise the host–microbe interface. Mechanistic studies were conducted in mouse colonoids, IBD biopsies and patient serum samples. Results DUOX2 activity increased permeability and bacterial translocation and induced subclinical inflammation in vTLR4 mice. GF vTLR4 mice had increased DUOX2 activity and permeability but no subclinical inflammation. In patients with IBD, DUOX2 expression was positively associated with plasma zonulin levels and negatively associated with ZO-1 expression. Engraftment of GF mice with IBD stool increased DUOX2 activity and triggered low-grade inflammation and permeability defects in mice. DUOX2 activity functionally altered the microbiome, reduced butyrate metabolism and promoted proinflammatory and pro-oncogenic bacterial metabolites. Butyrate and histone deacetylase (HDAC) inhibitors blocked DUOX2 activation and reversed its effects. Conclusions Elevated DUOX2 signalling contributes to epithelial barrier dysfunction, microbiome alterations and subclinical inflammation. Butyrate and HDAC inhibitors reversed these effects, indicating that DUOX2 may be a therapeutic target in IBD.
Year:
2025
Collaborators (3)
Jinmai Jiang
Research Assistant Professor
University of Florida
Christian Jobin
University of Florida
Maria T. Abreu
Executive Director
University of Miami Hospital
Make your next move.
Prepare your application
Review drafts before you send them.